Get started
Author

Lucy C. Riches

Observed names: L Riches, L. C. Riches, L. Riches, Lucy C. Riches (15070941), Lucy Catherine Riches, Lucy Riches, Riches, Lucy C
OpenAlex ID: A5067815172
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
2018 · Stephen T. Durant, Li Zheng, et al. · Science Advances · 316
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
2019 · Lucy C. Riches, Antonio G. Trinidad, et al. · Molecular Cancer Therapeutics · 165
Early events in the mammalian response to DNA double-strand breaks
2008 · L. C. Riches, A. M. Lynch, et al. · Mutagenesis · 122
Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2018 · Jeremy Karlin, Jasmine Allen, et al. · Molecular Cancer Therapeutics · 67
Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles
2018 · Elisabetta Leo, Jeffrey Johannes, et al. · Cancer Research · 23
Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents.
2009 · RS Finn, A Lau, et al. · Cancer Research · 7
Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer
2009 · Charlotte Knights, Christine Chresta, et al. · Molecular Cancer Therapeutics · 6
A molecular beacon approach to detecting RAD52 expression in response to DNA damage in human cells
2009 · Lucy C. Riches, Anthony M. Lynch, et al. · Toxicology in Vitro · 6
Abstract A104: AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models
2018 · Steve T. Durant, Kurt G. Pike, et al. · Molecular Cancer Therapeutics · 3
Abstract 3497: Identifying pre-clinical predictive biomarkers for the PARP inhibitor olaparib
2010 · Jonathan R. Dry, Alan Lau, et al. · Cancer Research · 1
Abstract 1775: Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells
2010 · Seock-Ah Im, Ahrum Min, et al. · Cancer Research · 1
Abstract #5494: Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer
2009 · Charlotte Knights, Lucy C. Riches, et al. · Cancer Research · 1
557 POSTER Pre-clinical activity of the PARP inhibitor AZD2281 in homologous recombination repair deficient triple negative breast cancer
2008 · M.J. O'Connor, A. Lau, et al. · European Journal of Cancer Supplements · 1
A molecular beacon approach for detecting DNA double strand breaks
2006 · Lucy C. Riches, Anthony M. Lynch, et al. · Toxicology · 1
Data from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Video 2 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Video 1 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Video 4 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Video 3 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Supplementary Information from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Supplementary Information from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
PDF
Video 3 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Video 4 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Video 2 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Video 1 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
2023 · Jeremy Karlin, Jasmine Allen, et al.
Works count: 33
Citation count: 720
H-index: 6
I10-index: 5
Year
Topic
Type